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Summary
In 40 western European patients with Stargardt disease
(STGD), we found 19 novel mutations in the retina-
specific ATP-binding cassette transporter (ABCR) gene,
illustrating STGD’s high allelic heterogeneity. One mu-
tation, 2588GrC, identified in 15 (37.5%) patients,
shows linkage disequilibrium with a rare polymorphism
(2828GrA) in exon 19, suggesting a founder effect. The
guanine at position 2588 is part of the 3′ splice site of
exon 17. Analysis of the lymphoblastoid cell mRNA of
two STGD patients with the 2588GrC mutation shows
that the resulting mutant ABCR proteins either lack
Gly863 or contain the missense mutation Gly863Ala.
We hypothesize that the 2588GrC alteration is a mild
mutation that causes STGD only in combination with
a severe ABCR mutation. This is supported in that the
accompanying ABCR mutations in at least five of eight
STGD patients are null (severe) and that a combination
of two mild mutations has not been observed among 68
STGD patients. The 2588GrC mutation is present in 1
of every 35 western Europeans, a rate higher than that
of the most frequent severe autosomal recessive muta-
tion, the cystic fibrosis conductance regulator gene mu-
tation DPhe508. Given an STGD incidence of 1/10,000,
homozygosity for the 2588GrC mutation or compound
heterozygosity for this and other mild ABCR mutations
probably does not result in an STGD phenotype.
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Introduction
Stargardt disease (STGD; MIM 248200) is the most
common autosomal recessive macular dystrophy, with
an estimated incidence of 1/10,000 (Blacharski 1988).
STGD is characterized by onset in the first or second
decade of life, decreased central vision, progressive bi-
lateral atrophy of the retinal pigment epithelium, and
the appearance of orange-yellow flecks distributed in the
posterior pole, sometimes extending beyond the vascular
arcade. A milder form of the same disorder, fundus fla-
vimaculatus (FFM), is generally characterized by a later
age at onset, slower progression, and more-widespread
distribution of the flecks (Stargardt 1909; Franceschetti
1963; Noble and Carr 1979). Linkage studies suggest
genetic homogeneity for the recessive forms of these dis-
eases. The STGD/FFM locus was first mapped to
1p22–p21 (Kaplan et al. 1993; Gerber et al. 1995), and
subsequently the critical area was refined to a 2-cM in-
terval between D1S406 and D1S236 (Anderson et al.
1995; Hoyng et al. 1996; Weber et al. 1996). In this
region, a gene encoding a retina-specific ATP-binding
cassette transporter protein (ABCR) was mapped, and
it was found to be involved in STGD/FFM (Allikmets
et al. 1997b). ABCR is a large gene consisting of 50
exons (Allikmets et al. 1997b; Azarian et al. 1998; Ger-
ber et al. 1998).
Heterozygous mutations in the ABCR gene were de-
scribed in 16% of patients with age-related macular de-
generation (AMD; MIM 153800), especially the “dry”
form of AMD (Allikmets et al. 1997a), indicating that
ABCR mutations could be a risk factor for this common
disease. Dryja et al. (1998) recently discussed the meth-
odology and statistical interpretation of the latter study.
Thirteen ABCR variants were identified in patients with
AMD but were not found, or were found in a lower
number, in racially matched controls. This difference,
however, was statistically significant only for
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Asp2177Asn and Gly1961Glu. Because of the enormous
allelic heterogeneity of the ABCR gene, statistical sig-
nificance for most mutations can be obtained only after
study of a much larger group of patients and controls
than studied by Allikmets et al. (1997a). On the basis
of the estimated incidence of AMD in the general pop-
ulation (30%) and the identification of ABCR mutations
in 16% of patients with AMD, heterozygous ABCR mu-
tations would be predicted to occur in 4.8% of the con-
trol group. If these mutations, when present in both
copies of the ABCR gene, invariably cause STGD, the
incidence of STGD would be six times the observed
frequency.
We and others have also implicated the ABCR gene
in retinitis pigmentosa (RP) and cone-rod dystrophy
(CRD), both of which are considered more severe phe-
notypes than STGD, and have proposed a model that
explains how different combinations of mutations can
cause distinct chorioretinal disorders (Martinez-Mir et
al. 1997, 1998; Rozet et al. 1997; Cremers et al. 1998;
van Driel et al. 1998). According to this model, the phe-
notype is determined by the residual activity of the
ABCR protein. The most severe phenotype, atypical RP,
is caused by the presence of two ABCR null alleles; CRD,
by a combination of a null allele and a moderately severe
mutation; and STGD, by compound heterozygosity of
a null mutation and a mild mutation or two moderately
severe mutations. In fact, in a consanguineous family
with individuals affected either by RP or by CRD, we
found homozygosity for a splice-site mutation
(IVS301GrT) in patients with RP, whereas patients
with CRD had compound heterozygosity for the
IVS301GrT and IVS405GrA mutations (Cremers
et al. 1998). The same IVS301GrT mutation was
identified in STGD patient 7560, who had compound
heterozygosity for this mutation and a 2588GrC mu-
tation. On the basis of this finding, we deduced that the
less severe CRD and STGD phenotypes in these patients
result from the moderate or mild effects on ABCR ac-
tivity of the accompanying mutation—that is,
IVS405GrA in CRD and 2588GrC in STGD—
compared with the severe effects in RP of IVS301GrT,
which we consider to be a genuine null allele (Cremers
et al. 1998; van Driel et al. 1998). The finding of a
homozygous null mutation (1847delA) in a consanguin-
eous family with RP was also reported by Martinez-Mir
et al. (1998).
Here, we report on a comprehensive mutation screen-
ing of the ABCR gene in 40 unrelated western European
patients with STGD. Nineteen new mutations were
found, including missense, nonsense, and splice-site mu-
tations as well as deletions. The 2588GrC mutation in
exon 17 was observed in more than one-third of all
patients with STGD. We propose that this mutation is
a frequent mild founder mutation in the western Eur-
opean population, which allows us to classify accom-
panying ABCR mutations as severe mutations and to
discuss implications for recurrence risk calculations and
genotype-phenotype correlations.
Material and Methods
Patients with STGD
Forty patients with STGD—29 fromTheNetherlands,
11 from Germany, and 5 from Sweden—were included
in the mutation analysis. The presence of the founder
mutation 2588GrC and the polymorphic variant
2828GrA was investigated in a larger group of 68 pa-
tients with STGD, mainly from The Netherlands (n 
) and from Germany ( ). Control individuals47 n  16
were from The Netherlands.
The family history of, and ophthalmologic informa-
tion on, the patients with STGD were reviewed by four
experienced ophthalmologists in three different centers,
the Department of Ophthalmology, Nijmegen (C.B.H.),
The Netherlands Ophthalmic Research Institute (N.T.),
and the Augenklinik, Heidelberg (K.R. and A.B.). For
the purpose of the study, the essential features of STGD
were the following: (1) a retinal disorder in families with
more than one affected individual, compatible with au-
tosomal recessive inheritance; (2) onset of symptoms be-
fore the age of 30 years; (3) bilateral central vision loss
with “beaten-metal” foveal changes and/or yellow pig-
ment epithelium deposits (“flecks”) in the posterior pole
of the eye; (4) normal caliber of the retinal vessels and
no pigmented bone-spicules in the retinal periphery; (5)
normal scotopic electroretinogram; and (6) typical “dark
choroid” in fluorescein angiography. Four STGD pa-
tients (numbers 7550, 8189, 8270, and 8272) showed
a relatively large number of flecks and therefore might
be considered to have the FFM type of STGD. Some
peripheral involvement was seen in three STGD patients
(numbers 8228, 8257, and 8434). We have not listed
the age at onset of the patients with STGD, which varies
from 10 to 30 years, because we observed a large in-
trafamilial variability.
All human studies were reviewed by the Nijmegen
Medical Ethics Commission. All individuals gave their
informed consent prior to inclusion in the study. Some
of the patient data included in this study have been an-
alyzed previously, either as part of an STGD linkage
study (Hoyng et al. 1996) or in a study describing the
molecular genetic analysis of a family with RP/CRD
(Cremers et al. 1998). Patient 8414 belongs to family
ST1, patient 7552 to family ST6, and patient 7569 to
family ST5 (Hoyng et al. 1996). The mutation analyses
of STGD patients 7560 and 8439 are described else-
where (Cremers et al. 1998).
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Table 1
Oligonucleotides Flanking ABCR Exons
EXON
FORWARD PRIMER REVERSE PRIMER
Ta
(C)aCode Sequence Code Sequence
1 1607 GGCTCTTAACGGCGTTTATG 1632 CCCCACAGTTCCAACCTG 55
2 1646 GACAAAAGGCCCAGACCAAAG 1647 GGATCTGAGGAGGGCTGTG 58
3 1635 GTCTCCATGACTAATCCCG 1636 ACTTCCTCCCCCGCATGG 55
5 1649 CCCATTTCCCCTTCAACAC 1681 TTGCCTTTCTCAGGCTGGG 56
6 1650 CTTTCCTACCACAGGGCAG 1750b AGGAATCACCTTGCAATTGG 58
8 1752 ATTGGCCTCACAGCAGATTA 1684 TTAACCAACATGAGAGGCC 56
11 1740 CAAGACCAAAGATCCTATGG 1686 GCTATNTTCAAGGGGCCCA 58
12 1744 GGTCCTCCTCACACTCTCTC 1688 AATTTCCCACTGACTTTGGAG 59
13 1745 GAGGTATGAGTGAGCTATCC 1746 CCCCCATTAGCGTGTCATG 58
14 1689 GTACAGAGCACTCTACTATTC 1747 GGGGAAAGGAACCAAAGTATTC 58
22 1965 CACCCTCCACAGCCCCTTAAC 1577c TCATTGTGGTTCCAGTACTCAG 58
NOTE.—Sequences 5′– 3′ of forward and reverse primers.
a Ta  annealing temperature.
b Reverse primer reported elsewhere by Gerber et al. (1998).
c Reverse primer reported elsewhere by Allikmets et al. (1997b).
SSCP and Sequence Analysis of the ABCR Gene
The oligonucleotides employed for SSCP and direct
sequencing of exons 4, 7, 9, 10, 15–21, and 23–50 are
described elsewhere (Gerber et al. 1998). The sequences
of the primers used to amplify the remaining exons are
given in table 1. DNA amplifications were performed in
96-well trays in a thermocycler (MJ Research). SSCPwas
performed by use of a 38:2 acrylamide:bisacrylamide
gel, with or without 10% (w/v) glycerol, at 4C. Nucleo-
tide sequence analysis was performed with a dye ter-
minator sequencing kit on an automated sequencer (Ap-
plied Biosystems 373), as described elsewhere (de Kok
et al. 1995).
Southern Blot Analysis
Southern blot analysis was performed as described
elsewhere (Huber et al. 1994). To show intragenic de-
letions, we hybridized pools of genomic DNA fragments
spanning exons 1–4, 15–25, 27, 33–36, 43–46, and 48
and analyzed EcoRI-digested genomic DNA of patients
with STGD.
Allele-Specific Oligonucleotide Hybridization Analysis
Allele-specific oligonucleotide (ASO) hybridization
and washing was performed as described by Shuber et
al. (1993).
Reverse Transcription (RT) and Nested PCR Analysis
To study the functional consequences of the splice-site
mutation in exon 17, we reverse transcribed the ABCR
mRNA by use of random hexamers and amplified the
cDNA by use of primers 2359f (5′-TGTCCATGCA-
GATGATGCTC-3′) and 2360r (5′-GGAGTCGTGT-
ATTCCTTCTG-3′). We followed this with a nested PCR
that used primers 2070f (5′-TGCGTGCTATGGCTTAC-
TCGC-3′) and 2071r (5′-TGGATCCTCCGTTTC
CTCTG-3′). The primary cDNA product encompasses
nt 2513–2748; the nested cDNA segment contains nt
2541–2721 (nucleotide numbering according to Allik-
mets et al. 1997b).
Statistical Analysis
One- and two-sided Fisher’s exact tests were used to
compare the frequencies of both the 2588GrC and
2828GrA alleles among patients with STGD (21/68 
0.309; 95% confidence interval [CI] 0.202–0.433) and
ethnically matched controls (2/154  0.013; 95% CI
0.002–0.046). This difference is highly significant (P !
) when either the one- or two-sided Fisher’s exact.001
test is applied. The 2828GrA variant was present with-
out the 2588GrC mutation in 0/68 patients with STGD
(95% CI 0.000–0.050) compared with 9/154 controls
(0.058; 95% CI 0.027–0.108). This difference is signif-
icant ( ) when the one-sided Fisher’s exact testP  .041
is applied but not when the two-sided test is used
( ). The probability of not finding oneP  .061
2828GrA allele without the 2588GrC mutation in 68
patients with STGD was calculated as 68(145/154) 
(95% CI 0.4%–15.5%). For this analysis, we did1.7%
not use data from the group of 311 controls, because
only half of them thus far have been investigated for the
presence of the 2828GrA variant. The 2588GrC mu-
tation was identified in 15/50 (0.3) mutantABCR alleles.
If we assume a random occurrence of the mild 2588GrC
mutation in patients with STGD, the a priori chance of
not finding any patient homozygous for this mutation
is (95% CI 0.0%–10.9%).2 68[1 (15/50) ]  0.2%
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For this calculation we used the heterozygote frequency
of mild ABCR mutations in the panel of 40 patients
with STGD, because this group was investigated com-
prehensively for mutations.
Results
Mutation Spectrum
To investigate the presence of mutations in the ABCR
gene of patients with STGD, we analyzed all 50 exons
of the gene by use of the PCR-SSCP technique, followed
by direct sequencing of exons showing aberrant migra-
tion. In addition, we performed Southern blot analysis
on ∼50% of the ABCR gene in patients with STGD by
using pools of ABCR exons as probes. We found 29
different mutations, 19 of which had not been reported
previously (table 2). In total, 50 mutations were iden-
tified in 80 putative ABCR alleles (62.5%). Missense
mutations constitute the largest group, accounting for
19 (38%) of 50 mutations. Five (10%) of the 50 mu-
tations are nonsense mutations, 7 (14%) are splice-site
mutations, and 3 (6%) are small deletions generating
frameshifts. In STGD patient 7679, a pool of genomic
probes consisting of exons 20–24 hybridized to an 8-kb
band instead of the normal 12-kb band (fig. 1). Hy-
bridization with each single exon as a probe showed the
lower band when exon 17, 19, or 23 was used but not
when exon 20, 21, or 22 was used (data not shown),
indicating the presence of a 4-kb deletion encompassing
exons 20–22. Finally, a GrC change at nt 2588—which
will be discussed later—accounts for 15 (30%) of the
50 mutations. Frameshift mutations all result in the trun-
cation of the second ABC-domain and are considered
pathological. To investigate the possibility that missense
and splice-site mutations represent polymorphic vari-
ants, we analyzed 100 control individuals from The
Netherlands. Except for the 2588GrC mutation, none
of these mutations was observed in the controls. Of the
40 patients with STGD, mutation analysis showed both
ABCR gene mutations in 14 patients (fig. 2), one ABCR
mutation in 22 patients, and no mutation in 4 patients.
Polymorphisms in the ABCR Gene
Sequencing of ABCR exons showed 14 nucleotide al-
terations that can be regarded as polymorphisms (table
3). Six DNA variants are silent mutations; four are in-
tronic changes that, according to Shapiro and Senapathy
(1987), are not predicted to affect splicing efficiency
when they are located in a splice site. Finally, four mis-
sense mutations (Arg943Gln, Asn1868Ile, Pro1948Leu,
and Ser2255Ile) have been found at a relatively high
frequency in the control population, by us or by others
(Allikmets et al. 1997a). Except for Arg943Gln, the oc-
currence of which is discussed later, carrier frequencies
in the control population are similar to heterozygote
frequencies in patients with STGD, which strongly sug-
gests that these amino acid changes do not contribute
to pathological lesions. The observed carrier frequencies
of these missense mutations in the general population
(6.9%–10.3%) are predicted to yield homozygotes for
these mutations at an incidence of ∼1/830–1/380. On
the basis of the known incidence of STGD, these mu-
tations, therefore, are unlikely to result in pathological
lesions.
The 2588GrC Mutation Is a Frequent Founder
Mutation in the Western European Population
Because of its high frequency in the group of patients
with STGD, we determined the presence of the
2588GrCmutation in 311 control individuals fromThe
Netherlands. By use of ASO hybridization analysis, we
ascertained that 9 (2.9%) of 311 control individuals car-
ried this mutation. We noticed a co-occurrence of the
2588GrC mutation with one of the polymorphisms,
2828GrA (previously denoted asArg943Gln; Allikmets
et al. 1997a), described. This suggested the possibility
that a 2588GrC mutation might have occurred on an
ABCR allele that carried the rare 2828GrA polymor-
phism. We therefore investigated a total of 68 patients
with STGD and 154 control individuals for the presence
of both variants. Most of the patients with STGD were
from The Netherlands ( ) or from Germanyn  47
( ). In figure 3, we show the ASO hybridizationn  16
result for 17 mers specific for the 2588GrC (fig. 3A, C)
and 2828GrA (fig. 3B, D) DNA variants in 40 of 68
tested patients with STGD and 4 patients with other
chorioretinal diseases (fig. 3A, B) and in 40 of 154 an-
alyzed control individuals (fig. 3C, D). Both ABCR gene
variations were found to coexist in 21 of 68 patients
with STGD (data partially shown, fig. 3A, B) and in 2
of 154 controls (data partially shown, fig. 3C, D). This
difference is highly significant ( ) when the two-P ! .001
sided Fisher’s exact test is applied. In contrast, the
2828GrA polymorphism alone, without co-occurrence
of the 2588GrC mutation, was found in 9 of 154 con-
trol individuals (data partially shown, fig. 3C, D) but
not in any of the 68 patients with STGD. This difference
is significant ( ) when the one-sided Fisher’s ex-P  .041
act test is applied but not significant ( ) whenP  .061
the two-tailed Fisher’s exact test is used. Clearly, nt
2588C and nt 2828A are in linkage disequilibrium, and
the high frequency of the 2588GrC mutation in the
western European population results from a founder ef-
fect. The founder mutation was virtually equally fre-
quent in Dutch ( ) and German15/47  31.9%
( ) patients with STGD.5/16  31.3%
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Figure 1 Southern blot analysis of 10 STGD patients’ genomic
DNA with a pool of genomic probes spanning exons 20–24. Patient
7679 (lane 8) shows a 4-kb deletion encompassing exons 20–22.
Table 2
Mutations in the ABCR Gene in 40 Patients with STGD
Exon DNA Change Effect
Cases
(n) Reference
Missense:
1 52CrT Arg18Trp 1a Gerber et al. (1998)
12 1622TrC Leu541Pro 1 Rozet et al. (1998)
13 1822TrA Phe608Ile 1 This study
16 2453GrA Gly818Glu 1 Allikmets et al. (1997b)
19 2870ArG Gln957Arg 1 This study
20 2932GrT Gly978Cys 1 This study
21 3113CrT Ala1038Val 2 Allikmets et al. (1997b)b
23 3335CrA Thr1112Asn 1 This study
30 4469GrA Cys1490Tyr 1 This study
35 4892TrC Leu1631Pro 1 This study
35 4918CrT Arg1640Trp 1 Rozet et al. (1998)b
38 5381CrA Ala1794Asp 1 This study
39 5537TrC Ile1846Thr 2 This study
42 5882GrA Gly1961Glu 2 Allikmets et al. (1997a)
44 6079CrT Leu2027Phe 1 Allikmets et al. (1997b)b
Nonsense:
1 45GrA Trp15stop 1 This study
14 2041CrT Arg681stop 1 This study
28 4200CrA Tyr1400stop 1 This study
28 4234CrT Gln1412stop 2 This study
Deletion:
2 108delT Frameshift 1 This study
20–22 del exons 20–22 Deletion/frameshift 1 This study
36 5161delAC Frameshift 1 This study
40 5668delTTC DelPhe1890 1 This study
Splice site:
6 768GrT Splice mutation 1 This study
16 IVS161GrA Splice mutation 1 This study
30 IVS301GrT Splice mutation 2 Cremers et al. (1998)
39 IVS396TrC Splice mutation 1 This study
40 IVS405GrA Splice mutation 2 Cremers et al. (1998)
Splice site/missense:
17 2588GrC DelGly863/Gly863Ala 15 Allikmets et al. (1997b)
a Homozygous.
b Data were erroneously published with a different nomenclature.
Consequences of the 2588GrC Mutation for the
ABCR mRNA and Predicted Protein
The 2588GrC mutation is located in the first nucle-
otide position of exon 17 (fig. 4A, upper panel) and
therefore is part of its splice acceptor site. The nucleotide
change could result in a missense mutation, causing an
exchange of an alanine for glycine at amino acid residue
863, but could also affect the splicing at the 3′ splice site
of exon 17. We identified a cryptic 3′ splice site 3 bp
downstream (nt 2591) in exon 17 (fig. 4A, lower panel).
According to Shapiro and Senapathy (1987), the splice
potential score of the normal splice site is 86.3, whereas
the score of the cryptic splice site is 81.2. The GrC
change at nt 2588 reduces the splice potential score of
the normal splice site to 80.3 and simultaneously in-
creases the score of the cryptic splice site to 92.9. We
hypothesized that the cryptic splice site might be used
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Figure 2 Patients with STGD in whom both ABCR mutations
were identified, with classification of each mutation on the basis of
the residual activity of the ABCR protein. In black boxes are indicated
mutations that cause a complete loss of ABCR activity; in gray boxes,
moderate mutations; and in white boxes, mild mutations. The
DelGly863/Gly863Ala mutation is considered a mild mutation, and
therefore all accompanying mutations are severe or null mutations.
The Tyr1400stop and 108delT mutations are also considered null mu-
tations, and therefore the accompanying mutations, Ala1794Asp and
Leu2027Phe, respectively, are considered mild mutations. Arg18Trp
has been found homozygously in patient 8434 and, according to the
model, is considered a moderate mutation. The classification of the
mutations in STGD patients 8316 and 8439 is described in detail in
the Discussion section. The mutations marked by one asterisk (*) were
previously found in patients with RP (homozygosity for
IVS301GrT) or patients with CRD (compound heterozygosity for
IVS301GrT and IVS405GrA [Cremers et al. 1998]). Patient 8439
(**) was found to carry a Leu541Pro as a third mutation. The
Ile1846Thr and Gly1961Glu mutations found in patient 8261 cannot
be classified.
Table 3
Polymorphisms in the ABCR Gene
Exon DNA Change aa Change/SPSa
Controlsb
(n [%])
19 2828GrA Arg943Gln 11/154 (7.1)
28 4203CrA Pro1401Pro ND
39 IVS38-10TrC SPS: 92.0r90.5 ND
40 5603ArT Asn1868Ile 11/108 (10.2)
40 5682GrC Leu1894Leu ND
42 IVS41-11GrA SPS: 94.4r94.4 ND
42 5843/4CArTG Pro1948Leu 9/130 (6.9)
42 5844ArG Pro1948Pro ND
45 6249CrT Ile2083Ile ND
46 6285TrC Asp2095Asp ND
48 6693CrT Ile2231Ile ND
48 IVS4821CrT ) ND
49 6764GrT Ser2255Ile 6/58 (10.3)c
49 IVS48-3TrC SPS: 87.3r95.6 ND
a SPS  splice potential score according to Shapiro and
Senapathy (1987).
b ND  not determined.
c Result reported by Allikmets et al. (1997a).
in the mutant allele, thereby resulting in a deletion of
Gly863.
To investigate the effect of the 2588GrC mutation,
we isolated RNA from Epstein-Barr virus–transformed
lymphoblastoid cells of a control individual and of two
STGD patients carrying the mutation, performed RT-
PCR, and amplified nt 2541–2721 of the ABCR cDNA
containing part of exon 16, exon 17, and part of exon
18. Nested PCR products showed a clear band at the
expected size (181 bp), an aspecific band of ∼200 bp,
and no evidence of smaller-sized products indicative of
exon 17 skipping (fig. 4B). Direct sequencing of themain
PCR product derived from a control individual showed
that only the normal splice site at position 2588 was
used (fig. 4D, panel I). In contrast, the cDNA from
STGD patients 7552 and 7560, both heterozygous car-
riers of the 2588GrC mutation, showed two overlap-
ping sequences, one being the result of cryptic splicing
at position 2591, causing the predicted 3-bp deletion,
and the other being a missense mutation resulting from
the splicing at the mutant cytosine at 2588 (fig. 4A, D,
panel II). PAGE analysis of [32P]-labeled cDNA PCR
products under denaturating conditions showed a sim-
ilar intensity of the signal from both transcripts, indi-
cating that the splice sites at positions 2588 and 2591
are approximately equally used (fig. 4C). In both pa-
tients, the cDNA product of the second allele, carrying
a different mutation not affecting exon 17, was not de-
tected. In the sequence displayed in figure 4D, panel II,
there is no evidence of a cytosine at 2588 in the reverse
sequence of the cDNA. Apparently, in both patients the
mutation on the other allele resulted in a very low quan-
tity or absence of the mRNA. Genomic sequencing
showed a splice-site mutation (768GrT) in exon 6 in
patient 7552; in patient 7560, a splice-site mutation
(IVS301GrT) was identified in exon 30.
Discussion
Identification of a Frequent Western European ABCR
Founder Mutation
Mutation analysis of the ABCR gene in 40 western
European patients with STGD yielded 29 different
ABCR mutations among a total of 50. One mutation
(2588GrC) is of particular interest because of its high
heterozygote frequency both among European patients
with STGD ( ) and among control indi-21/68  30.9%
viduals from the Dutch population (2.9%). There was
no significant difference between the heterozygote fre-
quency in Dutch ( ) and German15/47  31.9%
( ) patients with STGD. Very likely, the5/16  31.3%
population incidence of 2588GrC carriers in the
German population is similar to that in the Dutch. In
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Figure 3 ASO hybridization analysis of the 2588GrC mutation and the 2828GrA polymorphism in patients with STGD and control
individuals—analysis of the mutant cytosine at position 2588 (A) and the polymorphic adenine at position 2828 (B) in 40 patients with STGD
and 4 patients (lanes 5, 16, 30, and 34) with other chorioretinal diseases and analysis of the mutant cytosine at position 2588 (C) and the
mutant adenine at position 2828 (D) in 40 control individuals and STGD patient 7550 (lane 42). An approximately equal amount of DNA
was loaded onto the agarose gel and blotted. In B, lane 4, patient 7553 shows a weak signal. By sequence analysis, we have shown that this
results from overflow of material from lane 3.
the United States, this mutation was found at a much
lower heterozygote frequency both in patients with
STGD ( ) and in the control population13/150  8.7%
( ) (Allikmets et al. 1997a). A carrier fre-2/220  0.9%
quency of 2.9% is similar to that of another mild au-
tosomal recessive mutation, the IVS8-5T splice-site mu-
tation in the CFTR gene; approximately twice as high
as the carrier frequency of the most frequent severe au-
tosomal recessive mutation in The Netherlands, the
CFTR DPhe508 mutation (Tuerlings et al. 1998); and
similar to the carrier frequency of the 30delG mutation
in the connexin 26 gene in Mediterranean countries (De-
noyelle et al. 1997; Estivill et al. 1998). Surprisingly, the
2588GrC mutation was not mentioned at all by Rozet
et al. (1998), who analyzed 55 European and North
African patients with STGD/FFM for ABCR mutations.
Possibly, they did not consider this to be a pathological
mutation because of its high carrier frequency in the
control population.
The cytosine at 2588 is situated at the first position
of exon 17 and shows linkage disequilibrium with a
polymorphism (2828GrA) situated in exon 19. In all
21 patients with STGD and the two healthy individuals
known to carry the 2588GrC mutation, the 2828GrA
variant was also present. In the control population, the
2828GrA polymorphism was observed without the
2588GrC mutation in 9 (5.8%) of 154 individuals. We
did not, however, find the 2828GrA variant without the
2588GrCmutation in a total of 68 patients with STGD.
Given an occurrence of the single 2828GrA variant in
9 of 154 control individuals, the chance of not finding
this allele without the 2588GrCmutation in 68 patients
with STGD is highly unlikely ( ; 95% CIP  .017
0.004–0.155). From this we conclude that the 2588GrC
allele is the more recent and probably the pathological
mutation. Without a test that can assay ABCR activity,
it is difficult to assess the functional consequences of
both DNA variants. The 2828GrA alteration results in
a nonconservative Arg943Gln mutation. Our RT-PCR
studies suggest that the 2588GrC mutation does not
result in exon skipping but leads to a mixture of mutant
ABCR proteins either lacking Gly863 or carrying a non-
conservative Gly863Ala mutation. Whether the
2588GrC mutation acts on its own or synergistically
with the 2828GrA variant might be resolved when an
STGD patient carrying the 2588GrC—but not the
2828GrA—alteration is identified. Currently, we have
no explanation for the high carrier frequency of the
2588GrC ABCR mutation. By extending the haplotype
containing the 2588GrC ABCR mutation, we will in-
vestigate the extent of the observed linkage disequilib-
rium. Possibly a beneficial mutation in a closely linked
gene has resulted in the increased frequency of this mu-
tation. Alternatively, the high incidence might be attrib-
utable to genetic drift, a phenomenon that is not un-
common in the Dutch population (Peelen et al. 1997;
Petrij-Bosch et al. 1997).
Classification of ABCR Mutations
In the Introduction, we referred to a model that cor-
relates phenotypes in several chorioretinal disorderswith
the residual activity of the ABCR protein (Cremers et
al. 1998; Martinez-Mir et al. 1998; van Driel et al.
1998). In this model, ABCR mutations are classified as
mild, moderate, or severe, indicated in the scheme in
white, gray, or black boxes, respectively (fig. 5). On the
basis of the combinations of ABCR mutations identified
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Figure 4 RT-PCR analysis of the 2588GrC mutation in two STGD patients and a control. A, Potential splice variants for intron 16.
Upper scheme, normally spliced sequence; lower panel, splice variants using the mutant cytosine (nt 2588) and the adenine at nt 2591. The
former results in Gly863Ala; the latter, in DelGly863. Splice potential scores were determined by the method of Shapiro and Senapathy (1987),
where the frequencies of the 14 to 1 nucleotides in the 3′ splice sites are weighed. The asterisk (*) denotes the mutant cytosine. B, RT-PCR
results for a control (lane 1) and for patients 7552 (lane 2) and 7560 (lane 3). C, PAGE analysis of [32P]-labeled RT-PCR products shows
approximately equal intensities for the 181-bp RT-PCR product resulting from splicing at the mutant cytosine at 2588 and the 178-bp product
resulting from cryptic splicing at the adenine at 2591. Lane 1, control; lane 2, patient 7552; and lane 3, patient 7560. D, Sequence analysis of
the major PCR products shown in B. Panel I, reverse cDNA sequence of RT-PCR product of control; panel II, reverse cDNA sequences of the
two RT-PCR products of patient 7552. Because of the 3-bp deletion, the sequences following the mutant guanine at 2588 in the upper sequence
show overlapping peaks. For clarity, both mutant cDNA sequences are indicated. Triangles denote positions of the exon-exon junctions.
in patients with RP, CRD, and STGD, we proposed that
a combination of two severe mutations leads to an RP
phenotype and compound heterozygosity for a severe
and a moderate mutation leads to CRD, whereas a com-
bination of either a severe and a mild mutation or two
moderate mutations results in STGD (Cremers et al.
1998; van Driel et al. 1998). We also proposed, on the
basis of this model, that the 2588GrC mutation is a
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Table 4
Estimated Incidences of Combinations of Different Types of ABCR
Mutations and Predicted Associated Phenotypes
Combination of
ABCR Alleles Incidence Phenotype
Mild/ 1/25 Normala
Moderate/ 1/100 Normala
Severe/ 1/125 Normala
Mild/mild 1/2,500 Normala
Mild/moderate 1/10,000 Normala
Mild/severe 1/12,500 STGD
Moderate/moderate 1/40,000 STGD
Moderate/severe 1/50,000 CRD
Severe/severe 1/62,500 RP
a In these individuals, combinations of ABCR mutations might be
a risk factor for AMD.
Figure 5 Phenotype-genotype correlation for ABCR mutations depicting the inverse correlation between ABCR activity and the severity
of the associated chorioretinal disease. Combinations of null mutations (given in black boxes) invariably result in (atypical) RP; combinations
of null and moderately severe (gray boxes) mutations result in CRD; and combinations of two moderately severe mutations or a null mutation
and a mild mutation (white boxes) result in STGD; a single ABCR mutation might be a risk factor for developing AMD.
mild mutation, and that any mutation accompanying the
2588GrC mutation in a patient with STGD should be
a severe missense or a null mutation.
In 8/15 STGD patients with the 2588GrC mutation,
we found a mutation on the other ABCR allele (fig. 2).
In three of these patients—patients 7679, 8256, and
8387—the second mutation truncates the ABCR protein
and can be considered a null allele. RT-PCR results in-
dicate that in patient 7560, only the allele carrying the
2588GrC mutation generates a detectable transcript,
strongly suggesting that IVS301GrT is a severe mu-
tation (fig. 4B–D). RT-PCR analysis of RNA from STGD
patient 7552, who has compound heterozygosity for a
768GrT splice-site mutation and the 2588GrC founder
mutation, led to the same result, indicating that the
768GrT mutation also is a severe mutation (fig. 4B–D).
Moreover, we found the 768GrT mutation homozy-
gously in a patient with RP (current authors, unpub-
lished data). Two patients carried missense mutations.
The Gln957Arg mutation in STGD patient 8221 rep-
resents a nonconservative amino acid change located
nine amino acids aminoterminal to the first Walker A
motif. Moreover, the Gln957 residue is found also in
other members of the ABC1 subfamily (mouse Abcr,
mouse Abc1, mouse Abc2, and human ABCC [Luciani
et al. 1994; Klugbauer and Hofmann 1996; Azarian and
Travis 1997]). The Thr1112Asn mutation in STGD pa-
tient 7569 represents a conservative change, but all
members of the ABC1 subfamily contain a Thr at this
position, which is located 19 residues carboxyterminal
to a Walker B motif. Finally, patient 8433 shows a de-
letion of a Phe residue at position 1890, an amino acid
that is conserved in four of five members of the ABC1
subfamily and is located in the transmembrane domain
XII. Hence, in accordance with our model, most, if not
all, of the mutations accompanying the 2588GrC mu-
tation can be considered severe mutations.
We have also classified, on the basis of our model,
other mutations in different grades of severity (fig. 2).
The 4234CrT mutation in STGD patient 8257 and the
108delT mutation in patient 8360 are null mutations,
and therefore the respective accompanying mutations,
Ala1794Asp and Leu2027Phe, most likely are mild mu-
tations. In accordance with this classification, the
Leu2027Phe change is a conservative change, and the
Ala1794Asp exchange affects an amino acid residue that
is not conserved between the five members of the ABC1
subfamily. On the basis of the co-occurrence of the
IVS405GrA mutation with the IVS301GrT mu-
tation in a patient with CRD (Cremers et al. 1998), the
former mutation is considered a moderate mutation.
Consequently, the accompanying mutation in a patient
with STGD should also be a moderate mutation. Thus,
we classified the Ala1038Val mutation, which previously
was erroneously indicated as Ala1028Val (Lewis et al.,
in press), as a moderate mutation. In patient 8439, we
identified a third mutation, Leu541Pro, which is not
indicated in figure 2. Leu541Pro was also found to ac-
company the Ala1038Val mutation in a patient with
FFM, as described by Rozet et al. (1998), but not in our
patient 8316. Whether only one mutation or both mu-
tations, possibly acting in concert, contribute to path-
ological abnormalities cannot be predicted. Arg18Trp is
present homozygously in patient 8434 and therefore is
considered a moderate mutation. This is a nonconser-
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vative change that affects an amino acid residue found
in three of five members of the ABC1 subfamily. Simi-
larly, Arg1640Trp, which was found together with
Ala1038Val in patient 8316, was present homozygously
in a patient with STGD described by Rozet et al. (1998)
and therefore is a moderate mutation. Our data do not
allow us to classify the Gly1961Glu and accompanying
Ile1846Thr mutations found in patient 8261. We rec-
ognize that the proposed classification is not based on
functional studies of the ABCR protein and therefore
should be considered tentative. Clearly, to test this
model, future studies should focus on the elucidation of
the function of the ABCR protein.
Combinations of Severe/Severe and Mild/Mild ABCR
Mutations Do Not Cause STGD
On the basis of our results, one third to one half of
all ABCR mutations observed in patients with STGD
can be considered null mutations. Additional evidence
for the model depicted in figure 5 is the absence of null
mutations in both ABCR alleles of patients with STGD
in our study, as well as in ∼150 STGD patients from the
United States (Lewis et al., in press). The only suspicious
mutation in this respect is a homozygous deletion of five
amino acids (ValValAlaIleCys) after amino acid 1681 of
the ABCR protein, which affects the last predicted trans-
membrane domain of the ABCR protein (Allikmets et
al. 1997b). In our study, the 2588GrC mutation was
found in 15/50 mutant ABCR alleles. If the founder
mutation is present randomly in patients with STGD, 1/
11 patients with STGD, on average, would be predicted
to be homozygous for the 2588GrCmutation. Thus far,
we have not identified any homozygotes or compound
heterozygotes for this mild mutation in a total of 68
patients with STGD (this study; current authors, un-
published data [ ; 95% CI 0.000–0.109]). OnP  .002
the basis of the heterozygote frequency of the 2588GrC
mutation alone, homozygosity for this mutation would
be responsible for STGD in ∼1/4,800 individuals. On
the basis of a conservative estimate of a total carrier
frequency of all mild mutations of 1/25, homozygosity
or compound heterozygosity for two mild ABCR mu-
tations would occur in 1/2,500 individuals. To the best
of our knowledge, only one study has been performed
that estimates the incidence of STGD in the American
population at 1/10,000 (Blacharski 1988). Although we
cannot exclude the very real possibility that STGD is
underdiagnosed, it is clear that combinations of mild
mutations are unlikely to result in STGD. Recently,
Dryja et al. (1998) noted a discrepancy between the ob-
served frequency of ABCR variants in patients with
AMD, which yields a carrier frequency of ABCR mu-
tations in the general population of 4.8%, and the “ob-
served” frequency of 0.45%. In this calculation, Dryja
et al. (1998) included only the Asp2177Asn mutation,
excluding the 2588GrC mutation (given as Gly863Ala
by Allikmets et al. 1997a, 1997b) and the nonconser-
vative missense mutations Val643Gly and Gly818Glu.
Together, these mutations were found in 5/220 controls
(2.25%), much closer to the carrier frequency expected
on the basis of the incidence of AMD. As indicated
above, we here propose the existence of a relatively large
pool of mild ABCR variants in the general population,
which, when present in both ABCR alleles, do not lead
to STGD, RP, or CRD but may confer an increased risk
of developing AMD.
Estimates of Incidences of Mutant ABCR Alleles and
Their Involvement in CRD and RP
In table 4, we estimate the carrier frequencies of mod-
erate and severe ABCR alleles, as well as the incidences
of different retinal disorders associated with ABCR mu-
tations, on the basis of the following findings and as-
sumptions: (1) ∼25% of patients with STGD carry two
moderate mutations (see fig. 2); (2) the incidence of
STGD is ∼1/10,000 (Blacharski 1988); and (3) in view
of the carrier frequency of the founder mutation alone,
the total carrier frequency for mild mutations in the Eur-
opean population can conservatively be estimated as
∼0.04. Finally, to perform the following calculations, we
assume that a combination of mild/moderate mutations
does not result in STGD. If we assume an STGD inci-
dence of 1/10,000, the incidences of combinations of
mild/severe and moderate/moderate ABCR mutations
are ∼1/12,500 and ∼1/40,000, respectively. From this,
it follows that the carrier frequencies of severe and mod-
erate ABCR mutations will be ∼0.008 and ∼0.01, re-
spectively. From this calculation, we deduce that ABCR
mutations might be a relatively frequent cause of au-
tosomal recessive CRD and autosomal recessive RP. This
calculation also shows that healthy individuals have a
much greater chance to carry a mild than a severe ABCR
mutation, which has implications for STGD recurrence
risk calculations. On the basis of our calculations, a child
of a healthy individual and a patient with STGD has a
1 in 50 chance of inheriting a mild ABCR mutation, a
1 in 200 chance of inheriting a moderate mutation, and
a 1 in 250 chance of inheriting a severe mutation from
the healthy parent. In the majority of cases, the parent
with STGD will carry a mild and a severe ABCR mu-
tation, and the child will have a risk of ∼1/83
( ) of developing STGD, 1/400 of devel-1/100 1/500
oping CRD, and 1/500 of developing RP.
The questions remain whether combinations of mild/
mild and moderate/mild ABCR mutations increase the
risk of developing AMD and whether the classification
of ABCR mutations as proposed in this study also relates
to their penetrance in causing AMD. Given the high
carrier frequency of the 2588GrC mutation in western
Europe, some of these questions can now be addressed.
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Implications for STGD Linkage Analysis
The high carrier frequency of mild ABCR mutations
in the general population complicates linkage analysis
in the ∼1/50 families with STGD in which one of the
parents is predicted to carry two mild ABCR mutations.
Because this parent will not show retinal pathological
changes, the results of haplotype analysis will be mis-
leading. In a previous study, we indeed observed a family,
ST6, in which haplotype analysis demonstrated that one
affected female subject carries only one disease allele
(Hoyng et al. 1996). The affected subject (individual 5)
and her affected brothers carry a severe paternal
768GrT splice-site mutation, and her brothers both
carry the mild, maternally inherited founder mutation,
2588GrC, as well. A logical explanation would be that
her healthy mother carries two mild ABCR mutations.
We ruled out homozygosity of the mother for the
2588GrC mutation (current authors, unpublished
data), but she could very well have compound hetero-
zygosity for this mutation and another mild ABCR mu-
tation. Similarly, Anderson et al. (1995) described a fam-
ily with STGD (AR088) in which two affected siblings
apparently received different disease haplotypes from
one of their parents. Weber et al. (1996) found evidence
for nonallelic heterogeneity in 3/21 families with STGD,
which, in some cases, might be explained by the presence
of mild mutations in both ABCR alleles of one of the
parents in the respective families.
In conclusion, we have identified a remarkably fre-
quent mild ABCR mutation in the western European
population that enables a differentiation of ABCR mu-
tations into different classes of severity and that has im-
portant consequence for recurrence risk calculation in
families with STGD.
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